Single vs. short-course radiation for partial breast cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

The study compares two radiation schedules after lumpectomy: a single-dose (single fraction) partial breast irradiation versus the traditional multiple-dose (fraction) approach. It aims to see how each schedule affects quality of life, treatment-related side effects reported by both patients and providers, and local cancer control. Participants are women 40+ with small, early-stage tumors and suitable surgical and health profiles. Radiation delivery requires stabilization and immobilization; eligibility includes confirmed non-pregnancy for those of child-bearing potential. The trial is conducted at BC Cancer in Prince George, with the British Columbia Cancer Agency as lead sponsor.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Female participants age 40 or older
* Able to provide informed consent
* pTis-2 pN0 cM0 breast cancer, with tumor size \<3 cm as per provincial guidelines
* Able to complete electronic or paper entry of participant reported outcomes independently or with assistance from caregiver/family/friend/research staff
* Eastern Cooperative Oncology Group (ECOG) performance status 0 - 2
* A history and physical (clinical breast) examination, including ECOG performance status, performed within 8 weeks prior to enrollment.
* Participant is judged able to:

  * Maintain a stable position during therapy
  * Tolerate immobilization device(s) that may be required to deliver PBI safely
* Negative pregnancy test for People of Child-Bearing Potential (POCBP) within 4 weeks of RT start date

Exclusion Criteria:

* History of non-breast malignancies except adequately treated non-melanoma skin cancers, in situ cancers treated by local excision or other cancers curatively treated with no evidence of disease for ≥ 5 years.
* Uncontrolled concurrent malignant cancer
* Seroma not visible
* Ipsilateral implanted cardiac device
* Prior radiotherapy requiring summation for planning.
* Requirement for a radiation boost (as determined by the treating investigator)
* Positive surgical margins
* Surgical cavities lacking clear delineation (surgical clips are not required but may assist in target delineation)
* Known germline BRCA1/2 mutation.
* Serious medical comorbidities precluding radiotherapy (e.g., connective tissue disorders such as lupus or scleroderma)
* Pregnant or breastfeeding

Where it's running

• BC Cancer - Prince George
  Prince George, British Columbia, Canada Recruiting

Study contacts

• Principal investigator: Robert Olson, MD, MSc, FRCPC — BC Cancer - Prince George
• Study coordinator: Robert Olson, MD, MSC, FRCPC
• Email: rolson2@bccancer.bc.ca
• Phone: 250-645-7300

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Regular exercise to help women with early-stage breast cancer on hormone therapy

  This study tests whether a guided, 16-week exercise program improves quality of life and fitness for women with early-stage breast cancer who are starting adjuvant hormone therapy.

  Recruiting Fundación Investigación E Innovación Biomédica Hospital Universitario Infanta Sofia-Henares · San Sebastián de los Reyes, Madrid · NCT07893327

• Neoadjuvant Pyrotinib-to-pertuzumab for HER2-positive early breast cancer

  This trial tests whether a two-step neoadjuvant plan with Pyrotinib plus Trastuzumab and Docetaxel followed by Pertuzumab plus Trastuzumab and Docetaxel works better than four cycles of Pertuzumab plus Trastuzumab and Docetaxel in women with HER2-positive early- to locally advanced breast cancer.

  Recruiting Phase 3 Shanghai Jiao Tong University School of Medicine · Shanghai · NCT07797218

• Time‑restricted eating (8‑hour window) during chemotherapy for breast cancer: feasibility and acceptability

  This trial will test whether eating all daily food within an 8‑hour window is practical and acceptable for people starting chemotherapy for stage I–III breast cancer (and some stage IV with oncologist approval).

  Recruiting at 2 sites University of Illinois Chicago · Chicago, Illinois and 1 other locations · NCT07387445

• CPAP-assisted radiotherapy to lower heart and lung dose after breast-conserving surgery

  This tests whether wearing a CPAP breathing device during adjuvant radiotherapy can lower radiation exposure to the heart and lungs for women with early-stage (stage 1–3) breast cancer who had breast‑conserving surgery.

  Recruiting Phase 2/3 Universitaire Ziekenhuizen KU Leuven · Leuven · NCT07373782

• Oncoliq blood test for early detection of breast cancer

  This project will test whether a blood-based miRNA panel (the Oncoliq Test) can detect early breast cancer in adults 40–70 by comparing newly diagnosed, untreated patients with cancer-free controls.

  Recruiting Oncoliq US Inc · Buenos Aires, Buenos Aires · NCT07331506

• Adjuvant CDK4/6 Inhibitors in Older Breast Cancer Patients: Geriatric Screening in Action

  This study tests whether using geriatric screening alongside adjuvant CDK4/6 inhibitors helps tailor therapy for adults aged 70 and older with early-stage breast cancer.

  Recruiting at 4 sites Region Jönköping County · Gävle and 4 other locations · NCT07273357

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.